Mirum Pharmaceuticals, Inc.
volixibat
primary sclerosing cholangitis (PSC)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for volixibat in primary sclerosing cholangitis (PSC) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Volixibat VISTAS study in primary sclerosing cholangitis (PSC) topline data expected in Q2 2026.”